Literature DB >> 15223963

Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma.

Yukio Nakatani1, Yohei Miyagi, Tamiko Takemura, Teruaki Oka, Toyoharu Yokoi, Masayuki Takagi, Shigeo Yokoyama, Kenji Kashima, Kazuo Hara, Tetsuya Yamada, Akinori Nozawa, Yoshiaki Inayama, Kazuhiro Sakamoto, Nobuo Ogawa, Hitoshi Kitamura, Milan Resl, Sang-Ho Cho, Michael N Koss, Eugene J Mark.   

Abstract

It is now known that gene mutation of beta-catenin with subsequent nuclear/cytoplasmic (N/C) overaccumulation of the protein plays an important role in tumorigenesis of various organs. We recently demonstrated that low-grade adenocarcinoma of the fetal lung type (L-FLAC)/well-differentiated fetal adenocarcinoma (WDFA), the epithelial prototype of classic pulmonary blastoma (CPB), shows N/C localization of beta-catenin with genetic mutation. This prompted us to further investigate the state of beta-catenin abnormality in CPB and related neoplasms. We studied 9 lung tumors previously diagnosed as biphasic pulmonary blastoma (PB). Histologically, 4 cases (median age 34 years) were CPB with l-FLAC/WDFA as the epithelial component, whereas 5 cases (median age 65 years) were a variant of carcinosarcoma with high-grade FLAC/clear cell adenocarcinoma with fetal lung features as the epithelial component, which we term the blastomatoid variant of carcinosarcoma (BCS). Immunohistochemically, all 4 CPBs showed aberrant N/C localization of beta-catenin both in the epithelial and mesenchymal components, with especially high staining intensity in the budding glands and morules. In contrast, all 5 BCSs showed preserved or diminished membranous expression and no significant N/C expression of beta-catenin in the epithelial component, and absent or focal N/C expression of beta-catenin in the mesenchymal component. Mutational analysis of exon 3 of the beta-catenin gene revealed that 3 CPBs harbored missense mutations (S29F, S37F, and S37F), whereas none of the 5 BCSs had this mutation. This study suggests that beta-catenin gene mutations may play a role in the tumorigenesis of CPB. Although CPB and BCS have often been grouped together as biphasic PB, they are different entities based on immunohistochemical and molecular analysis of beta-catenin. Immunostaining for beta-catenin is useful for the discrimination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223963     DOI: 10.1097/00000478-200407000-00012

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Authors:  L V Sequist; R S Heist; A T Shaw; P Fidias; R Rosovsky; J S Temel; I T Lennes; S Digumarthy; B A Waltman; E Bast; S Tammireddy; L Morrissey; A Muzikansky; S B Goldberg; J Gainor; C L Channick; J C Wain; H Gaissert; D M Donahue; A Muniappan; C Wright; H Willers; D J Mathisen; N C Choi; J Baselga; T J Lynch; L W Ellisen; M Mino-Kenudson; M Lanuti; D R Borger; A J Iafrate; J A Engelman; D Dias-Santagata
Journal:  Ann Oncol       Date:  2011-11-09       Impact factor: 32.976

2.  Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study.

Authors:  Jing Zhang; Jian Sun; Xiao-Long Liang; Jun-Liang Lu; Yu-Feng Luo; Zhi-Yong Liang
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

3.  Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma.

Authors:  Takeshi Tamaki; Toshiki Shimizu; Maiko Niki; Michiomi Shimizu; Tohru Nishizawa; Shosaku Nomura
Journal:  Oncol Lett       Date:  2017-03-16       Impact factor: 2.967

4.  Combined large cell neuroendocrine carcinoma of the lung associated with low-grade fetal adenocarcinoma without β-catenin mutation: a case report.

Authors:  Xiaoming Xiong; Sibei Ruan; Cuiwei Zhang; Xiuli Xiao; Hanan Long
Journal:  Int J Clin Exp Pathol       Date:  2021-12-15

5.  Pulmonary well-differentiated fetal adenocarcinoma with platelet-derived growth factor receptor (PDGFR)α expression.

Authors:  Can-Qiao Luo; Sai-Ching J Yeung; Zhen-Guo Liu; Jun Meng; Fo-tian Zhong; Chao Cheng
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

6.  What do we know about pulmonary blastoma?: review of literature and clinical case report.

Authors:  Dorota Brodowska-Kania; Ewa Kotwica; Aleksandra Paturej; Witold Sośnicki; Janusz Patera; Agnieszka Giżewska; Stanisław Niemczyk
Journal:  Nagoya J Med Sci       Date:  2016-12       Impact factor: 1.131

Review 7.  Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature.

Authors:  Inga-Marie Schaefer; Carsten-Oliver Sahlmann; Tobias Overbeck; Stefan Schweyer; Jan Menke
Journal:  BMC Cancer       Date:  2012-09-25       Impact factor: 4.430

8.  Biphasic pulmonary blastoma: An unusual presentation with chest wall, rib, and pleural involvement.

Authors:  Ramakant Dixit; Nalin Joshi; Lokendra Dave
Journal:  Lung India       Date:  2014-01

Review 9.  Pulmonary blastoma: a case report and review of the literature.

Authors:  Robert J Smyth; Aurelie Fabre; Johnathan D Dodd; Waldemar Bartosik; Charles G Gallagher; Edward F McKone
Journal:  BMC Res Notes       Date:  2014-05-13

Review 10.  [Pneumoblastoma in adults: a new case report and literature review].

Authors:  Mustapha Azzakhmam; Fouad Zouaidia; Ahmed Jahidd; Zakia Bernoussi; Kaoutar Znati; Asmae Lakhdissi; Mohamed Bouchikh; Najat Mahassini
Journal:  Pan Afr Med J       Date:  2017-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.